Marco gives urologists and oncologists immediate access to updated prostate cancer evidence, from risk stratification to therapies in castration-resistant disease. The agent integrates EAU, NCCN and ESMO guidelines with data from trials on PARP inhibitors, radioligands and novel hormonal agents across all disease stages.
Some answers to questions we often receive
Yes. Marco synthesizes active surveillance eligibility criteria per EAU and NCCN (PSA <10, Gleason ≤6, fewer than 3 positive cores), recommended follow-up protocols and progression risk evidence, supporting the patient discussion about therapeutic options.
Marco integrates evidence on combining castration with docetaxel, abiraterone, enzalutamide, apalutamide or darolutamide in mHSPC, with data from LATITUDE, STAMPEDE, TITAN and ARCHES, and guideline recommendations by disease volume and performance status.
Marco includes definitions of biochemical recurrence after surgery and radiotherapy, recommended workup (including PSMA PET), salvage radiotherapy indications and hormonal therapy, based on current evidence from RAVES and RADICALS-HD.
Marco includes PROfound (olaparib) and TRITON2/3 (rucaparib) data for mCRPC with HRR gene alterations, patient selection criteria by mutation type (BRCA1/2 vs. other genes), guideline recommendations and the recommended molecular testing algorithm.
Yes. Marco integrates VISION trial data on lutetium PSMA-617 in mCRPC, patient selection criteria based on PSMA PET-scan expression, contraindications and sequencing relative to other treatment lines per updated EAU and NCCN guidelines.
Marco covers adverse effects of androgen deprivation therapy (osteoporosis, metabolic syndrome, cardiovascular risk), DXA and denosumab/zoledronic acid recommendations, and follow-up intervals per international guidelines.
The proliferation of active agents in prostate cancer — hormonal, PARP inhibitors, radioligands — makes it impossible to know the optimal sequence without evidence support.